

**WHAT IS CLAIMED IS:**

1. Isolated nucleic acid having a nucleotide sequence that has at least 80% nucleic acid sequence identity to:

(a) a DNA molecule encoding the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) a DNA molecule encoding the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) a DNA molecule encoding an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) a DNA molecule encoding an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(f) the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(g) the complement of (a), (b), (c), (d), (e) or (f).

2. Isolated nucleic acid having:

(a) a nucleotide sequence that encodes the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) a nucleotide sequence that encodes the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) a nucleotide sequence that encodes an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) a nucleotide sequence that encodes an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(f) the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(g) the complement of (a), (b), (c), (d), (e) or (f).

3. Isolated nucleic acid that hybridizes to:

(a) a nucleic acid that encodes the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) a nucleic acid that encodes the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) a nucleic acid that encodes an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) a nucleic acid that encodes an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

- (e) the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- (f) the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or
- (g) the complement of (a), (b), (c), (d), (e) or (f).
4. The nucleic acid of Claim 3, wherein the hybridization occurs under stringent conditions.
5. The nucleic acid of Claim 3 which is at least about 5 nucleotides in length.
6. An expression vector comprising the nucleic acid of Claim 1, 2 or 3.
7. The expression vector of Claim 6, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.
8. A host cell comprising the expression vector of Claim 7.
9. The host cell of Claim 8 which is a CHO cell, an *E. coli* cell or a yeast cell.
10. A process for producing a polypeptide comprising culturing the host cell of Claim 8 under conditions suitable for expression of said polypeptide and recovering said polypeptide from the cell culture.
11. An isolated polypeptide having at least 80% amino acid sequence identity to:
- (a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- (b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;
- (c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;
- (d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;
- (e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or
- (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).
12. An isolated polypeptide having:
- (a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- (b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;
- (c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;
- (d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;
- (e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or
- (f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

13. A chimeric polypeptide comprising the polypeptide of Claim 11 or 12 fused to a heterologous polypeptide.

14. The chimeric polypeptide of Claim 13, wherein said heterologous polypeptide is an epitope tag sequence or an Fc region of an immunoglobulin.

15. An isolated antibody that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

16. An isolated antibody that binds to a polypeptide having:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

17. The antibody of Claim 15 or 16 which is a monoclonal antibody.

18. The antibody of Claim 15 or 16 which is an antibody fragment.

19. The antibody of Claim 15 or 16 which is a chimeric or a humanized antibody.

20. The antibody of Claim 15 or 16 which is conjugated to a growth inhibitory agent.

21. The antibody of Claim 15 or 16 which is conjugated to a cytotoxic agent.

22. The antibody of Claim 21, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

23. The antibody of Claim 21, wherein the cytotoxic agent is a toxin.

24. The antibody of Claim 23, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

25. The antibody of Claim 23, wherein the toxin is a maytansinoid.

26. The antibody of Claim 15 or 16 which is produced in bacteria.

27. The antibody of Claim 15 or 16 which is produced in CHO cells.

28. The antibody of Claim 15 or 16 which induces death of a cell to which it binds.

29. The antibody of Claim 15 or 16 which is detectably labeled.

30. An isolated nucleic acid having a nucleotide sequence that encodes the antibody of Claim 15 or 16.

31. An expression vector comprising the nucleic acid of Claim 30 operably linked to control sequences recognized by a host cell transformed with the vector.

32. A host cell comprising the expression vector of Claim 31.

33. The host cell of Claim 32 which is a CHO cell, an *E. coli* cell or a yeast cell.

34. A process for producing an antibody comprising culturing the host cell of Claim 32 under conditions suitable for expression of said antibody and recovering said antibody from the cell culture.

35. An isolated oligopeptide that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

36. An isolated oligopeptide that binds to a polypeptide having:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355

(SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

37. The oligopeptide of Claim 35 or 36 which is conjugated to a growth inhibitory agent.

38. The oligopeptide of Claim 35 or 36 which is conjugated to a cytotoxic agent.

39. The oligopeptide of Claim 38, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

40. The oligopeptide of Claim 38, wherein the cytotoxic agent is a toxin.

41. The oligopeptide of Claim 40, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

42. The oligopeptide of Claim 40, wherein the toxin is a maytansinoid.

43. The oligopeptide of Claim 35 or 36 which induces death of a cell to which it binds.

44. The oligopeptide of Claim 35 or 36 which is detectably labeled.

45. A TAT binding organic molecule that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

46. The organic molecule of Claim 45 that binds to a polypeptide having:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown

in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

47. The organic molecule of Claim 45 or 46 which is conjugated to a growth inhibitory agent.

48. The organic molecule of Claim 45 or 46 which is conjugated to a cytotoxic agent.

49. The organic molecule of Claim 48, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

50. The organic molecule of Claim 48, wherein the cytotoxic agent is a toxin.

51. The organic molecule of Claim 50, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

52. The organic molecule of Claim 50, wherein the toxin is a maytansinoid.

53. The organic molecule of Claim 45 or 46 which induces death of a cell to which it binds.

54. The organic molecule of Claim 45 or 46 which is detectably labeled.

55. A composition of matter comprising:

(a) the polypeptide of Claim 11;

(b) the polypeptide of Claim 12;

(c) the chimeric polypeptide of Claim 13;

(d) the antibody of Claim 15;

(e) the antibody of Claim 16;

(f) the oligopeptide of Claim 35;

(g) the oligopeptide of Claim 36;

(h) the TAT binding organic molecule of Claim 45; or

(i) the TAT binding organic molecule of Claim 46; in combination with a carrier.

56. The composition of matter of Claim 55, wherein said carrier is a pharmaceutically acceptable carrier.

57. An article of manufacture comprising:

(a) a container; and

(b) the composition of matter of Claim 55 contained within said container.

58. The article of manufacture of Claim 57 further comprising a label affixed to said container, or a package insert included with said container, referring to the use of said composition of matter for the therapeutic treatment of or the diagnostic detection of a cancer.

59. A method of inhibiting the growth of a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-

6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein, the binding of said antibody, oligopeptide or organic molecule to said protein thereby causing an inhibition of growth of said cell.

60. The method of Claim 59, wherein said antibody is a monoclonal antibody.

61. The method of Claim 59, wherein said antibody is an antibody fragment.

62. The method of Claim 59, wherein said antibody is a chimeric or a humanized antibody.

63. The method of Claim 59, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

64. The method of Claim 59, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

65. The method of Claim 64, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

66. The method of Claim 64, wherein the cytotoxic agent is a toxin.

67. The method of Claim 66, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

68. The method of Claim 66, wherein the toxin is a maytansinoid.

69. The method of Claim 59, wherein said antibody is produced in bacteria.

70. The method of Claim 59, wherein said antibody is produced in CHO cells.

71. The method of Claim 59, wherein said cell is a cancer cell.

72. The method of Claim 71, wherein said cancer cell is further exposed to radiation treatment or a chemotherapeutic agent.

73. The method of Claim 71, wherein said cancer cell is selected from the group consisting of a breast cancer cell, a colorectal cancer cell, a lung cancer cell, an ovarian cancer cell, a central nervous system cancer cell, a liver cancer cell, a bladder cancer cell, a pancreatic cancer cell, a cervical cancer cell, a melanoma cell and a leukemia cell.

74. The method of Claim 71, wherein said protein is more abundantly expressed by said cancer cell as compared to a normal cell of the same tissue origin.

75. The method of Claim 59 which causes the death of said cell.

76. The method of Claim 59, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures

1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

77. A method of therapeutically treating a mammal having a cancerous tumor comprising cells that express a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), said method comprising administering to said mammal a therapeutically effective amount of an antibody, oligopeptide or organic molecule that binds to said protein, thereby effectively treating said mammal.

78. The method of Claim 77, wherein said antibody is a monoclonal antibody.

79. The method of Claim 77, wherein said antibody is an antibody fragment.

80. The method of Claim 77, wherein said antibody is a chimeric or a humanized antibody.

81. The method of Claim 77, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

82. The method of Claim 77, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

83. The method of Claim 82, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

84. The method of Claim 82, wherein the cytotoxic agent is a toxin.

85. The method of Claim 84, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

86. The method of Claim 84, wherein the toxin is a maytansinoid.

87. The method of Claim 77, wherein said antibody is produced in bacteria.

88. The method of Claim 77, wherein said antibody is produced in CHO cells.



89. The method of Claim 77, wherein said tumor is further exposed to radiation treatment or a chemotherapeutic agent.

90. The method of Claim 77, wherein said tumor is a breast tumor, a colorectal tumor, a lung tumor, an ovarian tumor, a central nervous system tumor, a liver tumor, a bladder tumor, a pancreatic tumor, or a cervical tumor.

5 91. The method of Claim 77, wherein said protein is more abundantly expressed by the cancerous cells of said tumor as compared to a normal cell of the same tissue origin.

92. The method of Claim 77, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

10 (b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

15 (e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

20 93. A method of determining the presence of a protein in a sample suspected of containing said protein, wherein said protein has at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

25 (c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

30 (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), said method comprising exposing said sample to an antibody, oligopeptide or organic molecule that binds to said protein and determining binding of said antibody, oligopeptide or organic molecule to said protein in said sample, wherein binding of the antibody, oligopeptide or organic molecule to said protein is indicative of the presence of said protein in said sample.

35 94. The method of Claim 93, wherein said sample comprises a cell suspected of expressing said protein.

95. The method of Claim 94, wherein said cell is a cancer cell.

96. The method of Claim 93, wherein said antibody, oligopeptide or organic molecule is detectably labeled.

97. The method of Claim 93, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

5 (b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

10 (d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

15 98. A method of diagnosing the presence of a tumor in a mammal, said method comprising determining the level of expression of a gene encoding a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

20 (b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

25 (e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

30 (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), in a test sample of tissue cells obtained from said mammal and in a control sample of known normal cells of the same tissue origin, wherein a higher level of expression of said protein in the test sample, as compared to the control sample, is indicative of the presence of tumor in the mammal from which the test sample was obtained.

99. The method of Claim 98, wherein the step of determining the level of expression of a gene encoding said protein comprises employing an oligonucleotide in an *in situ* hybridization or RT-PCR analysis.

35 100. The method of Claim 98, wherein the step determining the level of expression of a gene encoding said protein comprises employing an antibody in an immunohistochemistry or Western blot analysis.

101. The method of Claim 98, wherein said protein has:

- (a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- (b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;
- (c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;
- 5 (d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;
- (e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or
- (f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).
- 10

102. A method of diagnosing the presence of a tumor in a mammal, said method comprising contacting a test sample of tissue cells obtained from said mammal with an antibody, oligopeptide or organic molecule that binds to a protein having at least 80% amino acid sequence identity to:

- (a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- 15 (b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;
- (c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;
- (d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;
- 20 (e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or
- (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), and detecting the formation of a complex between said antibody, oligopeptide or organic molecule and said protein in the test sample, wherein the formation of a complex is indicative of the presence of a tumor in said mammal.
- 25

103. The method of Claim 102, wherein said antibody, oligopeptide or organic molecule is detectably labeled.

104. The method of Claim 102, wherein said test sample of tissue cells is obtained from an individual suspected of having a cancerous tumor.

30

105. The method of Claim 102, wherein said protein has:

- (a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- (b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;
- 35 (c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

106. A method for treating or preventing a cell proliferative disorder associated with increased expression or activity of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), said method comprising administering to a subject in need of such treatment an effective amount of an antagonist of said protein, thereby effectively treating or preventing said cell proliferative disorder.

107. The method of Claim 106, wherein said cell proliferative disorder is cancer.

108. The method of Claim 106, wherein said antagonist is an anti-TAT polypeptide antibody, TAT binding oligopeptide, TAT binding organic molecule or antisense oligonucleotide.

109. A method of binding an antibody, oligopeptide or organic molecule to a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), said method comprising contacting said cell with an antibody,

oligopeptide or organic molecule that binds to said protein and allowing the binding of the antibody, oligopeptide or organic molecule to said protein to occur, thereby binding said antibody, oligopeptide or organic molecule to said cell.

110. The method of Claim 109, wherein said antibody is a monoclonal antibody.

111. The method of Claim 109, wherein said antibody is an antibody fragment.

112. The method of Claim 109, wherein said antibody is a chimeric or a humanized antibody.

113. The method of Claim 109, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

114. The method of Claim 109, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

115. The method of Claim 114, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

116. The method of Claim 114, wherein the cytotoxic agent is a toxin.

117. The method of Claim 116, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

118. The method of Claim 116, wherein the toxin is a maytansinoid.

119. The method of Claim 109, wherein said antibody is produced in bacteria.

120. The method of Claim 109, wherein said antibody is produced in CHO cells.

121. The method of Claim 109, wherein said cell is a cancer cell.

122. The method of Claim 121, wherein said cancer cell is further exposed to radiation treatment or a chemotherapeutic agent.

123. The method of Claim 121, wherein said cancer cell is selected from the group consisting of a breast cancer cell, a colorectal cancer cell, a lung cancer cell, an ovarian cancer cell, a central nervous system cancer cell, a liver cancer cell, a bladder cancer cell, a pancreatic cancer cell, a cervical cancer cell, a melanoma cell and a leukemia cell.

124. The method of Claim 123, wherein said protein is more abundantly expressed by said cancer cell as compared to a normal cell of the same tissue origin.

125. The method of Claim 109 which causes the death of said cell.

126. Use of a nucleic acid as claimed in any of Claims 1 to 5 or 30 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

127. Use of a nucleic acid as claimed in any of Claims 1 to 5 or 30 in the preparation of a medicament for treating a tumor.

128. Use of a nucleic acid as claimed in any of Claims 1 to 5 or 30 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

129. Use of an expression vector as claimed in any of Claims 6, 7 or 31 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

130. Use of an expression vector as claimed in any of Claims 6, 7 or 31 in the preparation of

medicament for treating a tumor.

131. Use of an expression vector as claimed in any of Claims 6, 7 or 31 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

132. Use of a host cell as claimed in any of Claims 8, 9, 32, or 33 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

5 133. Use of a host cell as claimed in any of Claims 8, 9, 32 or 33 in the preparation of a medicament for treating a tumor.

134. Use of a host cell as claimed in any of Claims 8, 9, 32 or 33 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

135. Use of a polypeptide as claimed in any of Claims 11 to 14 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

136. Use of a polypeptide as claimed in any of Claims 11 to 14 in the preparation of a medicament for treating a tumor.

5 137. Use of a polypeptide as claimed in any of Claims 11 to 14 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

138. Use of an antibody as claimed in any of Claims 15 to 29 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

139. Use of an antibody as claimed in any of Claims 15 to 29 in the preparation of a medicament for treating a tumor.

10 140. Use of an antibody as claimed in any of Claims 15 to 29 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

141. Use of an oligopeptide as claimed in any of Claims 35 to 44 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

15 142. Use of an oligopeptide as claimed in any of Claims 35 to 44 in the preparation of a medicament for treating a tumor.

143. Use of an oligopeptide as claimed in any of Claims 35 to 44 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

144. Use of a TAT binding organic molecule as claimed in any of Claims 45 to 54 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

20 145. Use of a TAT binding organic molecule as claimed in any of Claims 45 to 54 in the preparation of a medicament for treating a tumor.

146. Use of a TAT binding organic molecule as claimed in any of Claims 45 to 54 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

25 147. Use of a composition of matter as claimed in any of Claims 55 or 56 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

148. Use of a composition of matter as claimed in any of Claims 55 or 56 in the preparation of a medicament for treating a tumor.

149. Use of a composition of matter as claimed in any of Claims 55 or 56 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

30 150. Use of an article of manufacture as claimed in any of Claims 57 or 58 in the preparation of a medicament for the therapeutic treatment or diagnostic detection of a cancer.

151. Use of an article of manufacture as claimed in any of Claims 57 or 58 in the preparation of a medicament for treating a tumor.

152. Use of an article of manufacture as claimed in any of Claims 57 or 58 in the preparation of a medicament for treatment or prevention of a cell proliferative disorder.

153. A method for inhibiting the growth of a cell, wherein the growth of said cell is at least in part dependent upon a growth potentiating effect of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, thereby inhibiting the growth of said cell.

154. The method of Claim 153, wherein said cell is a cancer cell.

155. The method of Claim 153, wherein said protein is expressed by said cell.

156. The method of Claim 153, wherein the binding of said antibody, oligopeptide or organic molecule to said protein antagonizes a cell growth-potentiating activity of said protein.

157. The method of Claim 153, wherein the binding of said antibody, oligopeptide or organic molecule to said protein induces the death of said cell.

158. The method of Claim 153, wherein said antibody is a monoclonal antibody.

159. The method of Claim 153, wherein said antibody is an antibody fragment.

160. The method of Claim 153, wherein said antibody is a chimeric or a humanized antibody.

161. The method of Claim 153, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

162. The method of Claim 153, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

163. The method of Claim 162, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

164. The method of Claim 162, wherein the cytotoxic agent is a toxin.

165. The method of Claim 164, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

166. The method of Claim 164, wherein the toxin is a maytansinoid.

167. The method of Claim 153, wherein said antibody is produced in bacteria.

168. The method of Claim 153, wherein said antibody is produced in CHO cells.



169. The method of Claim 153, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

170. A method of therapeutically treating a tumor in a mammal, wherein the growth of said tumor is at least in part dependent upon a growth potentiating effect of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

(b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;

(d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;

(e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, thereby effectively treating said tumor.

171. The method of Claim 170, wherein said protein is expressed by cells of said tumor.

172. The method of Claim 170, wherein the binding of said antibody, oligopeptide or organic molecule to said protein antagonizes a cell growth-potentiating activity of said protein.

173. The method of Claim 170, wherein said antibody is a monoclonal antibody.

174. The method of Claim 170, wherein said antibody is an antibody fragment.

175. The method of Claim 170, wherein said antibody is a chimeric or a humanized antibody.

176. The method of Claim 170, wherein said antibody, oligopeptide or organic molecule is conjugated to a growth inhibitory agent.

177. The method of Claim 170, wherein said antibody, oligopeptide or organic molecule is conjugated to a cytotoxic agent.

178. The method of Claim 177, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

179. The method of Claim 177, wherein the cytotoxic agent is a toxin.

180. The method of Claim 179, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

5 181. The method of Claim 179, wherein the toxin is a maytansinoid.

182. The method of Claim 170, wherein said antibody is produced in bacteria.

183. The method of Claim 170, wherein said antibody is produced in CHO cells.

184. The method of Claim 170, wherein said protein has:

(a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);

10 (b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

15 (d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).